cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Arvinas Inc
4 own
4 watching
Current Price
$31.24
$-1.12
(-3.46%)
logo-arvn
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,661.97M
52-Week High
52-Week High
81.1313
52-Week Low
52-Week Low
27.005
Average Volume
Average Volume
0.34M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,661.97M
icon52-Week High81.1313
icon52-Week Low27.005
iconAverage Volume0.34M
iconDividend Yield--
iconP/E Ratio--
What does the Arvinas Inc do?
Arvinas, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has a collaboration with Bayer AG to develop novel proteolysis-targeting chimera candidates for humans and plants. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.
Read More
How much money does Arvinas Inc make?
News & Events about Arvinas Inc.
Globe Newswire
1month ago
NEW HAVEN, Conn., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Brad Margus, M.B.A., has stepped down from the companys Board and Everett Cunningham has ...
Ticker Report
1month ago
Arvinas, Inc. (NASDAQ:ARVN Get Rating) has earned an average rating of Moderate Buy from the seventeen analysts that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and eleven have assigned a buy ...
Zolmax
2 months ago
Arvinas (NASDAQ:ARVN Get Rating) had its target price decreased by Cantor Fitzgerald from $106.00 to $90.00 in a report issued on Wednesday morning, The Fly reports. Several other analysts have also recently commented on ARVN. Morgan Stanley reduced their target price on shares of Arvinas from $63....
Globe Newswire
2 months ago
ARV-471 continues to show activity in heavily pre-treated patients with locally advanced or metastatic ER+/HER2- breast cancer Median progression free survival of 3.7 months in all patients and 5.7 months in patients with ESR1 mutant tumors support the initiation of two Phase 3 registrational trials...
Frequently Asked Questions
Frequently Asked Questions
What is Arvinas Inc share price today?
plus_minus_icon
Can Indians buy Arvinas Inc shares?
plus_minus_icon
How can I buy Arvinas Inc shares from India?
plus_minus_icon
Can Fractional shares of Arvinas Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Arvinas Inc stocks?
plus_minus_icon
What is today’s traded volume of Arvinas Inc?
plus_minus_icon
What is today’s market capitalisation of Arvinas Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Arvinas Inc?
plus_minus_icon
What percentage is Arvinas Inc down from its 52-Week High?
plus_minus_icon
What percentage is Arvinas Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$31.24
$-1.12
(-3.46%)
logo-arvn
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00